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PCardiac Magnetic Resonance in Infarction
Predicting Late Myocardial Recovery
and Outcomes in the Early Hours of
ST-Segment Elevation Myocardial Infarction
Traditional Measures Compared With
Microvascular Obstruction, Salvaged Myocardium,
and Necrosis Characteristics by Cardiovascular Magnetic Resonance
Eric Larose, DVM, MD, Josep Rodés-Cabau, MD, Philippe Pibarot, DVM, PHD,
Stéphane Rinfret, MD, MSC, Guy Proulx, MD, Can M. Nguyen, MD, Jean-Pierre Déry, MD, MSC,
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Jean-Rock Boudreault, MD, Marc Amyot, MSC, Robert De Larochellière, MD,
Olivier F. Bertrand, MD, PHD
Québec City, Québec, Canada
Objectives The aim of this study was to determine whether a very early imaging strategy improves the prediction of late
systolic dysfunction and poor outcomes in ST-segment elevation myocardial infarction (STEMI) compared with
traditional predictors.
Background Earlier prediction of poor outcomes after STEMI is desirable, because it will allow tailored therapy at the earliest
possible time, when benefits might be greatest.
Methods One hundred and three patients with acute STEMI were studied by contrast-enhanced cardiovascular magnetic
resonance within 12 h of primary angioplasty and at 6 months and followed 2 years. The primary end point
was left ventricular (LV) dysfunction, whereas poor outcomes were a key secondary end point.
Results Traditional risk factors were only modest predictors of late LV dysfunction. Late gadolinium enhancement (LGE)
volume maintained a stronger association to LV ejection fraction change than infarct transmurality, microvascu-
lar obstruction, or myocardial salvage during STEMI (p  0.02). Multivariable logistic regression identified LGE
volume during STEMI as the best predictor of late LV dysfunction (odds ratio: 1.36, p  0.03). An LGE 23% of
LV during STEMI accurately predicted late LV dysfunction (sensitivity 89%, specificity 74%). The LGE volume pro-
vided important incremental benefit for predicting late dysfunction (area under the curve  0.92, p  0.03 vs.
traditional risk factors). Twenty-three patients developed poor outcomes (1 death, 2 myocardial infarctions, 5
malignant arrhythmias, 4 severe LV dysfunction 35%, 11 hospital stays for heart failure) over 2.6  0.9 years;
LGE volume remained a strong independent predictor of poor outcomes, whereas LGE 23% carried a hazard
ratio of 6.1 for adverse events (p  0.0001).
Conclusions During the hyperacute phase of STEMI, LGE volume provides the strongest association and incremental predic-
tive value for late systolic dysfunction and discerns poor late outcomes. (J Am Coll Cardiol 2010;55:2459–69)
© 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.02.033c
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ong-term survival. After ST-segment elevation myocardial
nfarction (STEMI), patients who develop heart failure
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planted cardioverter-defibrillator
(AICD) implantation (2–4). Po-
tential benefits might arise from
earlier prediction and initiation
of preventive treatment for heart
failure during STEMI (5). How-
ever, left ventricular ejection
fraction (LVEF) assessment per-
formed very early after STEMI
See page 2489
does not reliably predict late
heart failure, because of hetero-
geneous LV remodeling and
healing (6). In addition, the or-
ganization of acute STEMI care
in many areas is based on cen-
tralized catheterization laborato-
ries receiving STEMI patients
directly from the field, to be trans-
ferred to a regional hospital 12 to
24 h after primary percutaneous
coronary intervention (PCI), un-
less the patient is considered
higher-risk and the transfer is de-
layed (7). Therefore, improved
strategies are essential in the very
early hours of STEMI to opti-
mally risk-stratify patients in order
to initiate tailored treatment in a
timely fashion and manage them
securely.
Late gadolinium enhancement
(LGE) measured by cardiovascu-
lar magnetic resonance imaging
(MRI) identifies necrosis burden
in the chronic phase after MI. In
this context, LGE predicts func-
tional recovery after revascular-
ization (8). However, suggestions
of “infarct shrinkage” observed
between the first week after in-
arction and later follow-up has raised the concern that
GE might not accurately assess myocardial damage due to
verestimation in the very early STEMI period, because it
ight represent a combination of necrosis and edema
omprising the area at risk (9). Alternate strategies includ-
ng the assessment of late microvascular obstruction (MVO)
nd myocardial salvage have been proposed (10,11). We
herefore studied whether infarct characteristics evaluated in
he early hours of STEMI improve the prediction of late LV
ystolic recovery and poor outcomes compared with tradi-
Abbreviations
and Acronyms
AICD  automated
implanted
cardioverter-defibrillator
AUC  area under the
curve
CE-CMR  contrast-
enhanced cardiovascular
magnetic resonance
CI  confidence interval
CK-MB  creatine kinase-
myocardial band
ECG  electrocardiogram
ED/ES  end-diastolic/
end-systolic
EF  ejection fraction
Gd  gadolinium
LAD  left anterior
descending coronary artery
LGE  late gadolinium
enhancement
LV  left ventricle/
ventricular
LVEF  left ventricular
ejection fraction
MACE  major adverse
cardiac events
MRI  magnetic resonance
imaging
MVO  microvascular
obstruction
OR  odds ratio
PCI  percutaneous
coronary intervention
ROC  receiver-operator
characteristic
SM  salvaged
myocardium
STEMI  ST-segment
elevation myocardial
infarction
STIR  short-TI inversion
recoveryional predictors. tethods
tudy population. We enrolled consecutive patients with
uccessfully reperfused acute STEMI in a prospective co-
ort study. The Institutional Review Board approved the
tudy, and all patients signed informed consent. Acute
TEMI was confirmed by: 1) presentation 12 h of typical
hest pain onset; 2) 1 mm ST-segment elevation in 2
ontiguous leads of electrocardiogram (ECG) (2 mm in
recordial leads); and 3) angiographically confirmed coro-
ary artery acute occlusion or subocclusion (Thrombolysis
n Myocardial Infarction flow grade 0 to 1). Exclusion
riteria were a recent MI or revascularization procedure (6
onths), shock requiring balloon counterpulsation (but
ressors were accepted), respiratory failure requiring me-
hanical ventilation (but oxygen by mask was accepted), and
tandard contraindications to cardiovascular MRI.
yocardial characterization by contrast-enhanced cardio-
ascular magnetic resonance (CE-CMR). Imaging was
erformed on a Philips Achieva 1.5-T system with a
hased-array cardiac coil, ECG gating, and breath-holding
n expiration (Philips Healthcare, Best, the Netherlands).
o assess CE-CMR during the hyperacute phase of
TEMI, protocol mandated imaging as early as logistically
easible, at the latest12 h after angiography. Cine imaging
or cardiac morphology and function was performed by
teady-state free precession technique in 8 to 14 parallel
hort-axis and 3 radial long-axis planes (8-mm thickness,
-mm gap) at 30 phases/cardiac cycle. Typical parameters
ncluded repetition time/echo time (TR/TE) of 3.4/1.2 ms,
ip angle 45°, number-of-excitations  1, yielding in-plane
patial resolution of 1.6  2 mm. A short-TI inversion
ecovery (STIR) pulse sequence (T2 STIR, TR 2 R-to-R
ntervals, TE 65 ms, TI 140 ms, slice thickness 15 mm,
eld-of-view 34 to 38 m, matrix 256  256) was per-
ormed with the body coil in 3 matched short-axis slices
basal, mid, apical) to identify myocardial edema (myocar-
ium 2 SDs of remote myocardium) and calculate area at
isk and salvaged myocardium (SM) (10). Resting first-pass
erfusion imaging was performed at 3 matched short-axis
ocations during rapid intravenous infusion of 0.05 mmol/kg
adolinium (Gd)-based contrast (Gd, gadodiamide, Omniscan,
E Healthcare, Mississauga, Ontario, Canada) with saturation-
ecovery imaging with a hybrid gradient-echo sequence.
ate Gd-enhanced imaging was acquired in matched short-
nd long-axis planes with a T1-weighted 2-dimensional
egmented inversion recovery gradient-echo sequence dur-
ng diastolic stand-still (8,12). The LGE imaging parame-
ers included repetition time/echo time 4.8/1.3 ms with
nversion time of 200 to 300 ms adjusted to null normal
yocardium 10 to 15 min after a cumulative total dose of
.2 mmol/kg Gd contrast.
Image analysis was performed offline in an experienced
ore laboratory with a standardized approach after the
6-segment model (CMR Mass version 6.2.3, Medis,
he Netherlands) (13,14). For ventricular volume analysis,
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June 1, 2010:2459–69 Predicting Late Recovery During Hyperacute STEMIhe endocardial border was determined for all 30 phases
f the cardiac cycle, and the cardiac phases that demon-
trated the largest and smallest ventricular cavity volumes
ere defined as end-diastole and -systole, respectively.
apillary muscles were included in the LV wall measure-
ents (equivalent to weighting the LV) and excluded from
V cavity measurements (equivalent to blood pool tech-
iques) (13). The LV end-diastolic volume, end-systolic
olume, stroke volume, EF, and mass were computed with
impson’s rule. The LV end-diastolic volume, end-systolic
olume, and mass were adjusted to body surface area
alculated by the Dubois formula (15). Segmental wall
hickness was measured at end-diastole (20 to 30 chords/
egment, by centerline method). Segmental thickening was
easured by comparing average chord thickening at end-
ystole in each segment. LV function was reported as a
ontinuous variable and also categorized as “normal” or
abnormal” (LVEF 50%) to reflect clinical practice (16).
yocardial edema was defined as a mean signal intensity
2 SDs of remote myocardium by semiautomatic software
etection on T2 STIR and reported as a percentage of total
yocardium on matched slices (10). Resting myocardial
erfusion was assessed by the kinetics of myocardial en-
ancement during rapid intravenous injection of Gd con-
rast (17). The LGE was quantified by semi-automatic
etection with the full-width at half-maximum approach as
reviously validated to maximize accuracy and reproducibil-
ty (18–22). The LGE size was reported in milliliters
ndexed to body surface area and calculated as a percentage
f total myocardium. We also performed segmental analysis
onsidering LGE to be “transmural” when LGE was at least
0% transmural in 50% of the segment’s total extension.
icrovascular obstruction was quantified by visual detection
n resting first-pass perfusion and reported as a percentage
f total myocardium on matched slices (11). Salvaged
yocardium was determined as the percent edematous
yocardium from T2 STIR that was not necrotic on
atched LGE (10).
ollow-up. Subjects were prospectively followed for a me-
ian of 33 months (range 24 to 42 months). Clinical
ollow-up based on a standard questionnaire was obtained
rom telephone interviews with the patients, relatives, or
hysicians or from hospital records. Survival status was
btained through a query of the government death index.
ardiovascular MRI was repeated at 6 months, because
tudies have demonstrated that infarct remodeling com-
letes by this time (23). We collected major adverse cardiac
vents (MACE) defined as death, new MI, malignant
rrhythmia (ventricular tachycardia/fibrillation), hospital
tay for heart failure, or LVEF 35%.
tatistical analysis. Our primary end points were change
n LVEF from STEMI to 6 months and LV dysfunction at
months. A key secondary end point was MACE as
efined in the preceding paragraph.
Baseline characteristics are presented as mean (95% CI)or continuous variables and percentages for categorical aata. Characteristics of patients with normal versus de-
reased 6-month LVEF were compared with a 2-tailed t
est for continuous variables and chi-square test for categor-
cal data. Changes in imaging variables from STEMI to 6
onths were assessed with paired t tests.
We performed univariable and multivariable linear re-
ression for association of variables measured during
TEMI with percentage change in LVEF at 6 months. We
lso performed multiple linear regression analysis to deter-
ine the strongest association between change in LVEF
nd key CE-CMR parameters, including LGE percentage,
onviable segments, MVO, and SM.
Then we fit logistic regression models to estimate unad-
usted odds ratios (ORs) with 95% confidence intervals
CIs) for: 1) LV dysfunction at 6 months; and 2) MACE.
e performed 2 multivariable logistic regression analyses to
ssess any independent association of measurements made
uring STEMI with 6-month LV dysfunction and MACE.
irst, we aimed to build the best overall parsimonious model
hat provided association to LV dysfunction and MACE late
fter STEMI: stepwise forward selection was performed con-
idering clinical or imaging variables listed in Tables 1 and 2
variable entry or stay at p  0.2). Second, we assessed the
ssociation of CE-CMR variables to 6-month dysfunction
nd MACE by adjusting for LVEF during STEMI and
reatine kinase-myocardial band (CK-MB) rise.
Furthermore, we performed receiver-operator character-
stic (ROC) analysis to identify an LGE percentage cutoff
redicting LV dysfunction at 6 months and MACE while
avoring superior sensitivity, to provide a better screening
ool to identify patients who will develop heart failure after
TEMI. The association between meeting this cutoff and
ACE was verified by Cox proportional hazards analysis.
inally, ROC analysis was performed to determine any
ncremental value in LGE percentage for LV dysfunction
eyond traditional risk factors; equality of the area under the
urves (AUC) was tested with the algorithm suggested by
eLong et al. (24).
All final models were tested for goodness-of-fit and for
nfluential observations to ensure that the assumptions of
egression were satisfied. Analyses were performed with Stata
ersion 9.2 (StataCorp LP, College Station, Texas) (25).
esults
ne hundred and four consecutive subjects were prospec-
ively studied. One was excluded between baseline and
ollow-up CE-CMR, because of dropout (claustrophobia).
he remaining 103 subjects constituted the study cohort
99% successful enrolment and follow-up). Two patients
ad follow-up cardiovascular MRI before 6 months because
rgent AICD implantation was scheduled for malignant
rrhythmia, and 2 did not have follow-up cardiovascular
RI because of new MI during the follow-up period
otentially altering the evolution of LVEF (adjudicated as
dverse events). Median time separating coronary angiog-
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.6 to 7.0 h). Significant LV dysfunction was present in 51%
uring STEMI and 30% at 6 months. Severe LV dysfunc-
ion (LVEF35%) was present in 10% during STEMI and
n 4% at 6 months. Demographic data and coronary artery
isease risk factors did not differ between those who later
STEMI Characteristics of the 101 Patients HaviMRI, and Comparison of Patients With and WithTable 1 STEMI Charact ris ics of the 101 PMRI, and Comparison of Patients W
Overall
(n  101
Age, yrs 58 (55–60
Male 77
Diabetes 8
Hypertension 34
Dyslipidemia 49
Smoking 52
Prior MI 14
Prior PCI or CABG 9
Killip class III or IV 17
Pain-to-balloon time, min 401 (289–5
Q waves on ECG at STEMI presentation 37
Sum ST-segment elevation, mm 8.4 (6.9–9.
GP IIb/IIIa inhibitor 97
Infarct culprit vessel
LAD 32
LCX 5
RCA 63
Target vessel residual diameter stenosis 10.3 (5.5–15
Maximum CK-MB elevation, mmol/l 163 (134–1
ASA at 6 months 97
Clopidogrel at 6 months 92
Statin at 6 months 92
Beta-blocker at 6 months 89
ACE inhibitor/ARB at 6 months 82
Atrial fibrillation at 6 months 3
Moderate/severe valve disease at 6 months 0
Values are percentages or mean (95% confidence interval), unless oth
culprit vessel left anterior descending coronary artery (LAD) versus no
ACE  angiotensin-converting enzyme; ARB  angiotensin recepto
CK-MB  creatine kinase-myocardial band; ECG  electrocardiogram
ejection fraction; MImyocardial infarction; PCI percutaneous coron
myocardial infarction.
TEMI Versus 6-Month CE-CMR Characteristicsor Entire Patient Population (n  101)Table 2 STE I Versus 6- ont CE-CMR Characteristicsfor Entire Patient Population (n  101)
STEMI 6 Months p Value
HR, beats/min 71 (68–73) 61 (59–63) 0.00001
CO, l/min/m2 2.0 (1.9–2.1) 2.0 (1.9–2.1) 0.50
LVEDVi, ml/m
2 58 (56–60) 59 (56–62) 0.50
LVESVi, ml/m
2 28 (26–31) 26 (23–29) 0.20
LVEF, % 51 (49–52) 57 (55–59) 0.00001
LGE volume, % LV 22 (19–25) 16 (14–19) 0.01
LGE volumei, ml/m
2 12 (11–14) 9 (7–11) 0.01
Transmural LGE segments, % 11 (8–13) 7 (5–9) 0.03
alues are mean (95% confidence interval). Lowercase “i” subscript specifies measurements that
ere indexed to body surface area.
CE-CMR  contrast-enhanced cardiovascular magnetic resonance; CO  cardiac output; HR 1
eart rate; LGE  late gadolinium enhancement; LVEDV  left ventricular end-diastolic volume;
VESV  left ventricular end-systolic volume; other abbreviations as in Table 1.eveloped LV dysfunction and those who did not, whereas
TEMI characteristics significantly differed by greater pain-
o-balloon time, presence of Q waves on ECG at STEMI
resentation, and maximum CK-MB elevation in those
ho later developed LV failure (Table 1). Three percent of
atients had treatment of STEMI with thrombus aspiration
nly, whereas all other patients underwent stenting (p 0.8
etween groups). All patients had Thrombolysis In Myo-
ardial Infarction flow grade 3 in the infarct-related artery
fter angiography and no significant residual diameter
tenosis (diameter stenosis 10.3%, 95% CI: 5.5 to 15.0%,
 0.3 between groups). The use of medications shown to
mprove LV recovery and prognosis was very high with no
ifference between groups, whereas other potential causes of
eart failure—including atrial fibrillation and significant
eart valve disease—were very low and did not differ
etween groups (Table 1).
The study population presented a broad range of LV
olumes and function during STEMI, which remodeled
ariably at 6 months (Table 2, Online Fig. 1). However,
espite an average absolute increase in LVEF of 5.8 
dergone Baseline and Follow-UpV Dysfunction at 6 Monthsts Having Undergone Baseline and Follow-Up
nd Without LV Dysfunction at 6 Months
6-Month LVEF <50%
(n  30)
6-Month LVEF >50%
(n  71) p Value
57 (52–62) 58 (55–60) 1.00
79 77 0.30
8 7 0.80
33 35 0.90
42 52 0.20
50 53 0.80
13 14 0.80
7 9 0.40
18 17 0.80
732 (397–1068) 280 (198–362) 0.0003
68 23 0.005
10.1 (6.1–14.1) 7.8 (6.3–9.2) 0.20
96 100 0.80
*
42 28
11 2
47 70
13.8 (3.19–24.5) 8.7 (3.5–13.9) 0.40
274 (208–340) 127 (99–155) 0.0001
100 96 0.8
100 87 0.6
90 94 0.9
89 89 1.0
88 78 0.7
2 3 0.9
0 0 1.0
pecified. *p 0.2 for overall difference in culprit vessel, p 0.07 for
er; ASA  acetylsalicylic acid; CABG  coronary artery bypass graft;
glycoprotein; LCX  left circumflex artery; LVEF  left ventricular
ervention; RCA right coronary artery; STEMI ST-segment elevationng Unout Latien
ith a
)
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June 1, 2010:2459–69 Predicting Late Recovery During Hyperacute STEMIatient varied widely between a maximum relative decrease
f 83% at 1 extreme and a maximum relative increase of 44%
t the other extreme (Fig. 1). In total, 28% of the cohort
ncurred LVEF deterioration during infarct healing; 33% of
Figure 1
Important Deterioration in LVEF Between Hyperacute
Phase of STEMI and 6-Month Follow-Up, and Corresponding
Infarct Characteristics at the Time of STEMI
Acute anterior ST-segment elevation myocardial infarction (STEMI) illustrating a
decrease in left ventricular ejection fraction (LVEF) from 44% during STEMI (A1:
end-diastole, A2: end-systole) to 24% at 6 months (E1 and E2). Area at risk is
visible on T2 short-TI inversion recovery imaging (B, green border), large necro-
sis is visible on late gadolinium enhancement (LGE) imaging (C, red border),
and microvascular obstruction is visible on first-pass perfusion imaging (D,
blue border). The LGE was measured at 42 ml/m2 or 55% of total LV myocar-
dial volume.the 52 patients without significant LV dysfunction at the
ime of STEMI (acutely compensated LVEF) developed
ystolic heart failure at 6 months (p  0.001 for category
hange from normal to abnormal). In addition, of the 30
atients with systolic dysfunction at 6 months, 7 (23%) were
cutely compensated (preserved LVEF) at the time of
TEMI.
Three additional major infarct characteristics were as-
essed, namely percentage of transmural LGE segments,
VO percentage, and SM percentage. An increase in
ercentage of transmural LGE segments was significantly
ssociated with a greater risk of late LVEF 50% in
nivariable analysis (OR: 1.93; 95% CI: 1.42 to 2.62, p 
.00001). To a larger degree, an increase in MVO percent-
ge was also associated with a significantly greater risk of
ate global LV dysfunction (OR: 11.0; 95% CI: 3.68 to 32.9,
 0.00001). In addition, an increase in SM percentage
as significantly associated with a decreased risk for late
VEF 50% (OR: 0.95; 95% CI: 0.87 to 0.99, p  0.02).
lthough each of these cardiovascular MRI-derived param-
ters has been investigated in different clinical contexts, we
ought to determine which (among LGE percentage, per-
entage of transmural segments, MVO percentage, or SM
ercentage) measured early during STEMI best predicted
lobal LVEF change over 6 months. Although univariable
nalysis indicated significant associations for all 4 parame-
ers with change in LVEF, only LGE percentage main-
ained significant associations with LVEF change in mul-
ivariate analysis (coefficient: 0.94; 95% CI: 1.81 to
0.14, p  0.02).
In the next step, we compared cardiovascular MRI
ariables with traditional predictors. Our first regression
nalysis tested for associations with percent change in
VEF from STEMI to 6 months. A first model built from
tepwise forward selection and a second model—built with
eft anterior descending (LAD) artery infarct, presence of
waves at presentation, LVEF during STEMI, maximum
K-MB rise, pain-to-balloon time, MVO, and SM—
onsistently identified LGE percentage (coefficient 1.27;
5% CI: 1.82 to 0.70, p  0.0001, from the second
odel) and LVEF (coefficient 1.21; 95% CI: 1.61 to
0.89, p  0.0001, second model) as the only variables
resent during STEMI that maintained significant inde-
endent associations to percentage change in LVEF from
TEMI to 6 months.
Afterward, we performed logistic regression to determine
ssociations with LVEF 50% at 6 months. After unad-
usted analysis (Table 3), we developed 2 multivariable
ogistic regression models to determine which variables from
yperacute STEMI best predicted LVEF 50% at 6
onths (Table 4). In the first stepwise multivariable ap-
roach built from the variables identified as significant in
nivariable analysis, LGE percentage was the only variable
elected in forming the best overall model for LV dysfunc-
ion at 6 months. In the second multivariable approach,
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Predicting Late Recovery During Hyperacute STEMI June 1, 2010:2459–69GE percentage in the hyperacute phase of STEMI main-
ained a significant association with 6-month LV dysfunc-
ion, independent of LVEF during STEMI and CK-MB
ise.
The occurrence of LV dysfunction at 6 months invariably
ncreased with greater LGE. The ROC analysis determined
hat a cutoff of 23% LGE measured at the time of
TEMI predicted 6-month LV dysfunction with a sensi-
ivity of 89%, specificity of 74%, positive likelihood ratio of
.6, and negative likelihood ratio of 0.1. This cutoff was
elected to screen for patients at risk for developing LV
ysfunction late after STEMI, correctly classifying 80% of
he population. The 23% LGE cutoff seemed useful in
ichotomizing 2 groups with widely diverging recoveries in
Unadjusted Analysis of ORs From VariablesMeas red During STEMI for 6-Month LVEF <50%Table 3 Unadju ted Analysis of ORs rom VMeasured During STEMI for 6-Mont
Age, yrs
Male
Hypertension
Dyslipidemia
Active/recent smoking
Diabetes
LDL-cholesterol on STEMI presentation, mmol/l
Blood glucose on STEMI presentation, mmol/l
ECG Q waves on STEMI presentation
ECG total ST-segment elevation on STEMI presentation, mm
LAD infarct territory
Pain-to-balloon time, min
Target vessel residual diameter stenosis*
Maximum CK-MB rise during STEMI, mmol/l
LVEDVi during STEMI, ml/m
2
LVESVi during STEMI, ml/m
2
LVEF during STEMI*
LV massi, g/m
2
LGE volume during STEMI, % LV
Transmural LGE segments during STEMI*
Microvascular obstruction during STEMI*
Salvaged myocardium during STEMI*
n  101. p value for univariable logistic regression. *Values given as
BSA  body surface area; CI  confidence interval; LDL  low-dens
Multivariable Associations of Variableseasured During Acu e STEMI With 6-Month LVTable 4 Multivariable Associa ion of VariabMeasured During Acute STEMI With
Best overall multivariable model by stepwise forward select
including all significant variables from Table 3
Presence of ECG Q waves at presentation
LGE during STEMI*
Pain-to-balloon time, min
Adjusted for LVEF during STEMI, LGE %, and CK-MB
LVEF during STEMI*
LGE during STEMI*
Maximum CK-MB rise after STEMI, mmol/l*Values given as percentages.
Abbreviations as in Tables 1 and 3.VEF from baseline to 6 months, across the entire range of
VEF quartiles during STEMI (Fig. 2).
We verified whether LGE percentage during STEMI
mproved the prediction of late LV dysfunction beyond
urrent risk factors. The ROC analysis indicated that LGE
ercentage measured during STEMI significantly improved
he diagnostic accuracy for 6-month LV dysfunction (AUC:
.92; 95% CI: 0.84 to 0.98) beyond pain-to-balloon time
AUC: 0.71; 95% CI: 0.60 to 0.82, p  0.001 compared
ith LGE percentage), CK-MB rise (AUC: 0.79; 95% CI:
.69 to 0.89, p  0.01), and LVEF during STEMI (AUC:
.84; 95% CI: 0.76 to 0.93, p  0.03) (Fig. 3). The
iagnostic accuracy of LGE percentage for predicting late
V dysfunction did not differ, whether the infarct territory
les
F <50%
OR 95% CI p Value
1.00 0.96–1.04 1.00
2.40 0.43–10.1 0.30
1.02 0.38–2.83 0.90
0.44 0.17–1.11 0.10
0.71 0.29–1.74 0.80
1.13 0.21–6.23 0.90
1.80 0.93–3.48 0.08
1.04 0.89–1.21 0.70
6.80 2.16–21.5 0.001
1.06 0.97–1.16 0.20
1.92 0.77–4.76 0.20
1.10 1.03–1.17 0.005
1.01 0.99–1.03 0.40
1.47 1.24–1.75 0.00001
1.10 1.05–1.15 0.00001
1.16 1.08–1.23 0.00001
0.87 0.82–0.93 0.00001
1.11 1.05–1.18 0.00001
17.00 8.47–34.1 0.00001
1.93 1.42–2.62 0.00001
11.00 3.68–32.9 0.00001
0.95 0.87–0.99 0.02
ages.
protein; OR  odds ratio; other abbreviations as in Tables 1 and 2.
50%
onth LVEF <50%
OR 95% CI p Value
6.27 0.81–74.9 0.08
1.33 1.09–1.78 0.002
1.15 1.01–1.32 0.09
0.95 0.88–1.03 0.20
1.36 1.11–1.66 0.004
1.00 0.99–1.01 0.40ariab
h LVEEF <les
6-M
ion
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June 1, 2010:2459–69 Predicting Late Recovery During Hyperacute STEMIFigure 2 Relative Change in LVEF From STEMI to 6-Month Follow-Up, Assessed According to Quartiles of LVEF During STEMI
The LGE 23% during STEMI identifies a subgroup of patients with significantly worse functional recovery
compared with those with less LGE, across the entire range of LVEF quartiles during STEMI. Abbreviations as in Figure 1.Figure 3 Receiver-Operator Characteristic Curves for LV Dysfunction at 6 Months
There is significant added value of LGE percentage during STEMI (per 1%, area under the receiver-operator characteristic curve [AUC]: 0.92) compared with traditional
measures including LVEF during STEMI (per 1%, AUC 0.84, p  0.03 vs. LGE), maximum creatine kinase-myocardial band (CKMB) (per 1 mmol/kg, AUC 0.79, p  0.01
vs. LGE), and pain-to-balloon time (per 1 min, AUC 0.71, p  0.001 vs. LGE) for the prediction of LV dysfunction at 6 months. Abbreviations as in Figure 1.
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on-LAD infarct, p  0.3) and whether Q waves were
resent or not at STEMI presentation (AUC 0.93 for
waves present vs. 0.88 for Q waves absent, p  0.3).
We additionally explored clinical outcomes: over 2.3 
.4 year follow-up, MACE occurred in 23 (22%) subjects (1
eath, 2 MIs, 5 malignant arrhythmias requiring AICD, 4
evere LV dysfunction 35%, 11 hospital stays for heart
ailure). The previously defined cutoff of LGE 23%
easured during hyperacute STEMI incurred a significant
isk of adverse events by univariable Cox proportional
azards regression (hazard ratio: 10.1; 95% CI: 3.7 to 27.3,
 0.0001) (Fig. 4). In addition, LGE percentage re-
ained independently associated with MACE in multiva-
iable Cox regression that included CK-MB rise and LVEF
uring STEMI (hazard ratio: 1.72; 95% CI: 1.43 to 2.01,
 0.007).
iscussion
he major finding of this study is that LGE quantification
ery early during STEMI predicts late heart failure and
dverse events beyond traditional risk factors such as infarct
erritory, maximum CK-MB rise, pain-to-balloon time,
resence of Q waves, and LVEF during STEMI. A second
ajor finding is that, during the hyperacute phase of
TEMI, LGE volume incurred the strongest association to
V function change, beyond infarct transmurality, MVO,
nd SM. Significant variability in preload and afterload
onditions and difficulty in discriminating stunned from
onviable myocardium at the time of STEMI have rendered
ost early variables imperfect predictors of late systolic
unction and adverse events. However, strategies for the
arliest possible risk assessment after STEMI have become
ssential not only to better target therapies but also to
ntroduce these therapies in the timeliest manner while
Figure 4 Kaplan-Meier Event-Free Survival Estimates for LGE >
Number at risk reports the number of patients that entered the respective interval
of patients who presented an event in the respective interval. LGE  late gadoliniuenefits might be greatest. We have demonstrated that,
uring STEMI, LGE percentage is the strongest predictor
f late heart failure and adverse events, opening the door to
mproved strategies for very early risk stratification.
VEF measurement after STEMI. Considerable effort
as gone toward earlier risk stratification and faster imple-
entation of prognosis-altering interventions in high-risk
TEMI (5,26). Treatment strategies based on residual
VEF after STEMI have shown important survival benefits
2–4,27). However, LVEF measured very early after MI is
n imperfect predictor of later LVEF recovery: normal
lobal EF at the time of STEMI might beget low EF in
ater months—as observed in this study and others—likely
s a result of the gradual disappearance of the compensatory
ncreased contractility of healthy segments and remodeling
6,26). In addition, low EF at the time of STEMI might
eget normal EF after infarct healing, as systolic dysfunc-
ion observed early after STEMI might be due to a
ombination of reversible myocardial stunning and irrevers-
ble necrosis (28,29). The failure of recent treatment strat-
gies such as AICD implantation based on assessment of
VEF very early after STEMI, contrary to the success
bserved when LVEF was measured 40 days after MI,
ight be due to the observed variability in LV remodeling
uring early infarct healing (3,30).
redictors of residual systolic function after infarct healing
nd remodeling. Systolic function after STEMI varies as
function of the infarct territory (31), the sum of ST-
egment elevation on ECG (32,33), microvascular dysfunc-
ion (34,35), time to reperfusion (36), and time to peak CK
37). Although LVEF at the time of STEMI has been
orrelated to late systolic function in early studies (34), this
as since been called into question by more accurate
adionuclide (38) and volumetric techniques (9). In fact, LV
emodeling is a particularly heterogeneous process, difficult
Versus LGE <23% Very Early During STEMI
-free, minus one-half of the number
ancement; other abbreviations as in Figure 1.23%
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erritory, stunning, and the success of reperfusion including
resence of collateral circulation and reversal of coronary
hrombosis (39). In addition, global LVEF also relies on
ompensatory alterations of the remote territories that
epend on circulation in the non–infarct-related coronary
rteries and changes in local wall stress related to remodel-
ng (40). A comprehensive assessment of LV remodeling
redicting residual LVEF after infarct healing requires the
onsideration of all these variables. Our study demonstrates
hat, during this hyperacute period of STEMI, the predic-
ive value of LVEF might be significantly improved by
GE measurement.
GE during and after STEMI. The evolution of LV
unction over the first months after MI has been described
ith volumetric techniques (9,41–44). In a study of 20
ubjects imaged within 1 week of acute MI and at 2 months,
ngkanisorn et al. (9) described an average 5% increase in
VEF and a 34% decrease in LGE. In another study
xamining 22 patients after primary PCI for STEMI, Baks
t al. (45) described a 31% decrease in LGE between 5 days
nd 5 months after MI. These studies were not powered to
xamine multivariate predictors of LVEF after infarct heal-
ng. In addition, because of the measured decreases in LGE,
oncern was raised that early assessment of LGE might not
e reliable. Although it has been suggested that LGE in the
cute phase of STEMI might overestimate true infarct size
ither because of peri-infarct edema or partial volume effects
9,46), animal studies report that LGE during STEMI
epresents real myocardial tissue alterations (47), and there-
ore the observed decrease likely represents scar involution
48). Our study importantly adds that LGE during the
yperacute phase of STEMI holds a strong independent
ssociation with late heart failure and adverse events and
herefore is likely biologically significant and not a simple
verestimation.
otential mechanisms underlying the predictive value of
GE during STEMI. Prior studies have reported associ-
tions between LGE measured within 1 week of MI and
VEF at 3 to 12 months; however, they could not take into
ccount other risk factors or explore clinical outcomes. Wu
t al. (49) have recently concluded that early LGE was a
tronger predictor of clinical events than LVEF or LV
nd-systolic volume but did not take into account other
nfarct characteristics such as area at risk or salvaged
yocardium. In addition, this study was performed outside
he “hyperacute window” of STEMI, because patients were
valuated within 1 week, compared with within 12 h
median 4.5 h) in the present study. Although it seems likely
hat very early assessment might further improve patient
are by allowing earlier risk stratification and more rapid
nitiation of tailored therapies, this remains to be demon-
trated. Our study is the first step toward the evaluation of
his strategy. We conclude in the STEMI population that
nfarct size measured by LGE carries a stronger associationith heart failure and poor outcomes than traditional risk
actors or other infarct characteristics.
tudy limitations. We aimed to study the widest possible
ange of STEMI cases. Nevertheless, those requiring bal-
oon counterpulsation or mechanical ventilation were ex-
luded, because of logistical concerns and/or contraindica-
ions to cardiovascular MRI. In our current practice setting,
owever, mechanical ventilation or balloon counterpulsation
re required in3% of STEMI subjects. Although it might
e argued that our population does not seem to carry severe
isease, we present a faithful snapshot of contemporary
TEMI with a representative rate of adverse events (Online
ig. 1). In addition, the definition of transmural necrosis we
sed was dichotomous (yes/no) on the basis of semiauto-
atic measurements of necrosis “thickness” along 20 to 30
hords/segment; although this provides objective measure-
ents, it might differ from reports that define transmurality
isually by 25% increments. Finally, given the relatively
imited sample size, and despite a parsimonious statistical
pproach, it remains possible that our findings might be at
east in part explained by some overfitting of regression
odels. Of the 2 logistic regression models developed to
etermine associations with LVEF 50%, the first model
sed stepwise forward selection including all significant
ariables from univariable analysis, therefore rendering it
usceptible to overfitting and possibly yielding an overly
ptimistic model; however, the second model was adjusted
nly for LVEF during STEMI, LGE percentage, and
K-MB, therefore satisfying the prerequisites to avoid
verfitting. Despite these potential limitations, our study is
he largest to date investigating CE-CMR characteristics
ery early during STEMI, and seeking to clarify the added
alue of CE-CMR compared with traditional strategies by
ultivariate regression and ROC analysis. Our conclusions
rovide statistically sound and important data contributing
o improved risk stratification early during STEMI.
onclusions
his study demonstrates that, very early during STEMI,
GE volume is an accurate predictor of heart failure and
dverse events, providing important incremental value be-
ond traditional risk factors, MVO, and myocardial salvage.
isk stratification based on CE-CMR infarct imaging very
arly during STEMI might improve tailoring of prognosis-
ltering therapies in patients who will likely benefit most
rom aggressive treatment.
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